New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
04:55 EDTTHOR, THOR, THOR, THOR, HTWR, HTWR, HTWR, HTWR, GILD, GILD, GILD, GILD, DNA, DNA, DNA, DNA, BAYRY, BAYRY, BAYRY, BAYRY, ALIOF, ALIOF, ALIOF, ALIOF, SSH, SSH, SSH, SSH, UTHR, UTHR, UTHR, UTHRInternational Society for Heart & Lung Transplantation to hold annual meeting
34th Annual Meeting of ISHLT is being held in San Diego, California on April 10-13.
News For THOR;HTWR;GILD;DNA;BAYRY;ALIOF;SSH;UTHR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 21, 2015
06:58 EDTGILDGilead May weekly volatility elevated into Q1 and outlook
Subscribe for More Information
April 20, 2015
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
07:29 EDTHTWR, THORCanaccord would be buyers of Thoratec following favorable ISHLT
Subscribe for More Information
07:26 EDTHTWRHeartWare weakness a buying opportunity, says Canaccord
Subscribe for More Information
07:20 EDTGILDAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
07:18 EDTDNA, BAYRYAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
April 17, 2015
07:58 EDTTHORThoratec to hold an investor and analyst meeting
Subscribe for More Information
05:35 EDTTHORThoratec announces positive results from ROADMAP study
Thoratec announced results from the ROADMAP Study, or the Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients. For the primary endpoint, a composite of survival and functional improvement, ROADMAP demonstrated a statistically significant benefit of HeartMate II LVAD support relative to optimal medical management in ambulatory NYHA Class IIIB/IV heart failure patients. Survival in the HeartMate II group was 80% at one year, compared with 64% for medically managed patients on an as-treated basis. At one year of follow-up, 39% of patients within the HeartMate II group met the primary endpoint of survival on the original therapy along with a 75 meter increase in six minute walk test distance, compared with 21% of patients on optimal medical management, representing a statistically significant difference.
April 16, 2015
19:00 EDTSSHOn The Fly: After Hours Movers
Subscribe for More Information
16:56 EDTSSHSunshine Heart says FDA requested minor protocol changes in COUNTER HF study
Subscribe for More Information
12:19 EDTBAYRYBayer downgraded to Equal Weight from Overweight at Morgan Stanley
Subscribe for More Information
10:04 EDTTHORHigh option volume stocks
Subscribe for More Information
09:52 EDTHTWR, THORThoratec comments on HeartMate II data in ENDURANCE therapy trial
Subscribe for More Information
08:53 EDTTHOR, HTWRBofA/Merrill medical technology analysts hold analyst/industry conference call
Subscribe for More Information
05:32 EDTHTWRHeartWare achieves primary endpoint in ENDURANCE clinical trial
Subscribe for More Information
April 15, 2015
16:01 EDTGILDOptions Update; April 15, 2015
iPath S&P 500 VIX Short-Term Futures down 49c to 21.90. Option volume leaders: AAPL NFLX C PBR KMI RIG MCP TWTR GILD BAC according to Track Data.
07:41 EDTBAYRYEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 14, 2015
10:03 EDTTHORThoratec management to meet with Oppenheimer
Subscribe for More Information
April 13, 2015
16:01 EDTGILDOptions Update; April 13, 2015
Subscribe for More Information
09:34 EDTGILDActive equity options trading on open
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use